Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.

In China, HIV-1-infected patients typically receive antiretroviral therapy (ART) that includes lamivudine (3TC) as a reverse-transcriptase inhibitor (RTI) (ART-3TC). Previous studies from certain developed countries have shown that, in ART-3TC, 3TC-resistant HBV progressively emerges at an annual ra...

Full description

Bibliographic Details
Main Authors: Lijun Gu, Yang Han, Yijia Li, Ting Zhu, Xiaojing Song, Ying Huang, Feifei Yang, Shuo Guan, Jing Xie, Jin Gohda, Noriaki Hosoya, Ai Kawana-Tachikawa, Wenjun Liu, George Fu Gao, Aikichi Iwamoto, Taisheng Li, Takaomi Ishida
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4543549?pdf=render

Internet

http://europepmc.org/articles/PMC4543549?pdf=render

Similar Items